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Abstract 
Background: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP 
is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma 
(DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a 
difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL 
patients aged 19-88 years, but data on elderly patients have not been reported in detail so 
far. Here, we provide a subgroup analysis of patients ≥60 years treated on the R-
CHOP14v21 trial with extended follow-up.  
Patients and Methods: 604 R-CHOP14v21 patients ≥60 years were included in this subgroup 
analysis, with a median follow-up of 77.7 months. To assess the impact of MYC 
rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we 
performed a joint analysis of cases with available molecular data from the R-CHOP14v21 
(N=217) and RICOVER-60 (N=204) trials. 
Results: Elderly DLBCL patients received high dose intensities with median total doses of 
≥98% for all agents. Toxicities were similar in both arms with the exception of more grade ≥3 
neutropenia (P<0.0001) and fewer grade ≥3 thrombocytopenia (P=0.05) in R-CHOP-21 vs. 
R-CHOP-14. The elderly patient population had a favorable 5-year overall survival (OS) of 
69% (95%CI: 65-73). We did not identify any subgroup of patients that showed differential 
response to either regimen. In multivariable analysis including individual factors of the IPI, 
gender, bulk, B2M and albumin levels, only age and B2M were of independent prognostic 
significance for OS. Molecular analyses demonstrated a significant impact of MYC-R 
(HR=1.96; 95%CI: 1.22-3.16; P=0.01) and DHL (HR=2.21; 95%CI: 1.18-4.11; P=0.01) on OS 
in the combined trial cohorts, independent of other prognostic factors. 
Conclusions: Our data support equivalence of both R-CHOP application forms in elderly 
DLBCL patients. Elderly MYC-R and DHL patients have inferior prognosis and should be 
considered for alternative treatment approaches. 
 
Trial numbers: ISCRTN 16017947 (R-CHOP14v21); NCT00052936 (RICOVER-60) 
Key words 
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 3
Key message 
We provide a detailed outcome analysis of elderly patients with DLBCL treated with 2- or 3-
weekly R-CHOP within the UK R-CHOP14v21 trial, indicating equivalence of both regimens 
in the elderly patient population. In a joint analysis of R-CHOP14v21 and RICOVER-60 
molecular data, we demonstrate that MYC rearrangements and double-hit-lymphoma are 
independent poor prognostic factors in elderly DLBCL.  
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Introduction 
Elderly patients with diffuse large B-cell lymphoma (DLBCL) have a worse prognosis 
compared to the younger patient population. This is partly explained by lower treatment 
tolerability in elderly patients with difficulties to administer adequate doses of chemotherapy. 
However, even when receiving comparable treatment intensities, elderly DLBCL patients 
have inferior outcome, potentially indicating more aggressive disease biology. Therefore, 
dose-intensified administration of R-CHOP immuno-chemotherapy might be of particular 
benefit for elderly DLBCL patients to overcome these high-risk factors. Treatment of patients 
>60 years (y) with 6x R-CHOP-14 plus 2x rituximab in the German RICOVER-60 trial has 
achieved the best long-term outcome in elderly DLBCL patients published to date.1 However, 
superiority of dose-intensified R-CHOP-14 compared to the 3-weekly administration in elderly 
DLBCL patients could not be demonstrated in randomized trials. 
The GELA LNH03-6B trial comparing R-CHOP-14 and R-CHOP-21 in DLBCL patients aged 
60-80y showed no difference of either regimen,2 but results were criticized due to high 
treatment-related mortality and low dose intensities in the R-CHOP-14 arm. The UK NCRI R-
CHOP14v21 trial compared the 2- and 3-weekly R-CHOP regimens in DLBCL patients aged 
18-88y and similarly did not observe a difference in outcome across age groups.3 However, 
outcomes of the elderly R-CHOP14v21 trial cohort have not been reported separately and it 
remained unclear whether particular subgroups of elderly patients benefit from intensified 
treatment. 
The International Prognostic Index (IPI) is widely used for prognostication of younger and 
elderly DLBCL patients. Due to differences in disease biology and outcomes it has been 
proposed to use separate prognostic scores for the elderly patient group,4,5 but these have 
not yet been validated in large independent cohorts.  
Several molecular high-risk markers have been identified in DLBCL that could potentially 
refine clinical prognostic models. Cell-of-origin (COO) assessment of DLBCL according to 
gene-expression-profiling separates the germinal center B-cell (GCB) and the poor 
prognostic activated B-cell (ABC) subtypes, but these analyses lack prospective validation 
and methodological problems currently limit their use in standard practice. The negative 
prognostic impact of MYC rearrangements (MYC-R) as well as MYC- and concomitant BCL2- 
or BCL6 rearrangements (double-hit lymphoma; DHL) has been shown in several DLBCL 
cohorts.6,7 The prognostic significance of MYC-R seems to be particularly high in older 
DLBCL patients.6 Due to the low incidence of MYC-R and DHL and possibly due to their age-
dependent relevance, an independent prognostic significance of these markers in 
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multivariate models has not yet been demonstrated in prospective trial cohorts of R-CHOP-
treated patients.  
The aim of this subgroup analysis was to provide detailed outcomes and toxicity data on 
elderly patients treated within the R-CHOP14v21 trial and to investigate the impact of clinical 
and molecular factors on outcome in this age group. 
Patients and Methods 
Patient characteristics in the R-CHOP14v21 trial have been published in detail.3 A brief 
description of the trial is given in the Supplement (available at Annals of Oncology online).  
Of 1080 R-CHOP14v21 patients, 604 were ≥60y and included in the current analysis. Details 
of statistical analyses are provided in the Supplement. 
COO was assessed by the immunohistochemistry (IHC)-based Hans algorithm. Assessment 
of MYC-, BCL2- and BCL6-rearrangements was done with fluorescence in-situ hybridization 
(FISH; N=217). DHL was defined as presence of MYC- and either BCL2- or BCL6-
rearrangements. In order to increase the sample size to assess the impact of MYC-R and 
DHL on outcome in elderly DLBCL patients, we performed a joint analysis with data from 204 
elderly DLBCL patients treated on the RICOVER-60 trial who had molecular results available 
(Table S1). Details of the German high-grade non-Hodgkin lymphoma study group 
(DSHNHL) RICOVER-60 trial and methods of molecular analyses within the trial have been 
previously described.1,7 
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Results 
We included 604 elderly patients from the R-CHOP14v21 trial in this subgroup analysis. 
Patients’ median age was 67y (range 60-88). Baseline characteristics were well balanced 
between treatment arms (Table 1). There was a trend towards a higher rate of BCL6 
rearrangements and DHL in R-CHOP-14 (P=0.10 and P=0.06, respectively).  
Dose intensities were high in both trial arms. Median total doses of cyclosphosphamide, 
doxorubicin, vincristine, prednisolone and rituximab received were 98% vs. 99%, 98% vs. 
99%, 100% vs. 100%, 98% vs. 100%, and 98% vs. 98% in R-CHOP-21 and R-CHOP-14, 
respectively. Seventy one (24%) patients on R-CHOP-21 and 46 (15%) patients on R-CHOP-
14 did not complete all treatment cycles (P=0.01). Reasons for early treatment termination 
are listed in Table S2, with treatment-related toxicity being the most common cause. 
Frequency of dose reductions was similar in both arms (15% for R-CHOP-21 vs. 16% for R-
CHOP-14; P=0.73).  
Treatment toxicities are given in Table 2. There was evidence of more grade ≥3 neutropenia 
(62% vs. 36%; P<0.0001) and less grade ≥3 thrombocytopenia (7% vs. 12%; P=0.05) in R-
CHOP-21 compared to R-CHOP-14. Patients on R-CHOP-21 had lower incidence of anemia 
(20% vs. 31%; P=0.001), with a similar trend for grade ≥3 anemia (2% vs. 5%; P=0.11). No 
significant difference in the incidence of fever and infections or any other toxicity was 
observed. The incidence of treatment-related deaths, fatal cardiac events and secondary 
malignancies were similar in both arms (Table S3). 
Response was assessable in 274 patients in each arm. There was no evidence of a 
difference in response rates between R-CHOP-21 and R-CHOP-14 [complete response 
(CR)/unconfirmed CR (CRu): 67% vs. 62%, P=0.21; overall response rate (ORR) both 91%; 
Table 3]. CR/CRu rates after 4 cycles of therapy were 39% and 33%, respectively (P=0.15). 
61% and 60% of patients are still alive without progression (Table S3). Four patients on R-
CHOP-21 and seven on R-CHOP-14 presented with central nervous system relapse 
(P=0.55).  
After a median follow-up of 77.7 months, there was no evidence of a difference in 
progression-free survival (PFS) and overall survival (OS) between treatment arms in patients 
≥60y or ≥70y (Figure 1A/B). No difference in survival between R-CHOP-21 and R-CHOP-14 
was observed in patients who only achieved partial response (PR) after 4 cycles (P=0.79 for 
PFS; P=0.68 for OS). There was also no difference between treatment arms with respect to 
gender (P=0.54 for PFS; P=0.67 for OS) or IPI (P=0.64 for PFS; P=0.50 for OS). 5y-PFS was 
64% (95%CI: 60-68) in patients ≥60y and 58% (95%CI: 51-65) in patients ≥70y. 5y-OS was 
69% (95%CI: 66-73) and 61% (95%CI: 54-68), respectively.  
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63/280 (23%) patients with available data received consolidation radiotherapy. Of those, 36 
had initial bulk, 20 extranodal disease, and 10 had both. Disease status before radiotherapy 
was available for 61 patients: 23 (37%) CR/CRu, 31 (51%) PR, 7 (12%) SD. In patients with 
PR or SD who are supposed to benefit most from radiotherapy, the use of radiotherapy was 
not associated with OS (Figure S3).  
In multivariable analysis, only age and B2M levels were of independent prognostic 
significance for OS (Table S4). There was no significant impact of COO subtypes on 
outcomes (Figure S1). When comparing prognostic scores IPI, R-IPI, E-IPI and ABE4 (Table 
S5; Figure S2), ABE4 achieved the best fit and discrimination for predicting OS, followed by 
the IPI. Similar results were obtained for PFS (data not shown).  
To assess the impact of MYC-R and DHL on outcome we performed a joint analysis with 
cases from RICOVER-60. 23/217 (11%) patients from our cohort and 19/204 (9%) patients 
from RICOVER-60 had MYC-R as determined by FISH. 14/215 (7%) and 9/182 (5%) had 
DHL, respectively. MYC-R and DHL cases had significantly worse OS compared to cases 
without these abnormalities [HR=1.96 (95%CI: 1.22-3.16); P=0.01 and HR=2.21 (95%CI: 
1.18-4.11); P=0.01, respectively); Figure 2]. Similar effect sizes were observed after 
adjusting for individual IPI factors and trial arms [HR=1.76 (95%CI: 1.09-2.85); P=0.02 and 
HR 2.08 (95%CI: 1.11-3.90); P=0.02, respectively)]. The difference in OS between DHL and 
MYC-R was not significant (HR=1.38 (95%CI: 0.55-3.43; P=0.49). There was no significant 
impact of BCL2- or BCL6-rearrangements on OS (P=0.34 and P=0.99, respectively). 
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Discussion 
With a median follow-up of 6.5y, we provide a detailed analysis of outcome and toxicities 
from patients with newly diagnosed DLBCL aged ≥60y treated on the phase 3 R-
CHOP14v21 trial.  
Elderly DLBCL patients in our cohort had an excellent long-term outcome with 5y-OS of 69% 
(3y-PFS 71%; 3y-OS 76%). These results are similar to data from elderly DLBCL patients 
treated with 6x R-CHOP-14 on RICOVER-60 (3y-PFS 73%; 3y-OS 78%) and better than 
outcomes in the GELA LNH03-6B trial (3y-PFS 61%; 3y-OS 73%).1,2 Of note, patients’ 
median age was higher in LNH03-6B (70y) compared to our cohort (67y) and RICOVER-60 
(68y). In addition, there were more cases presenting with high IPI (3-5) in the LNH03-6B trial 
(75% vs. 57% in our subgroup vs. 43% in RICOVER-60), which might have contributed to 
inferior outcome seen in this trial population. 
Toxicity profiles in our cohort of elderly DLBCL patients were favorable in both treatment 
arms. As expected, patients on R-CHOP-21 had a higher incidence of neutropenia probably 
due to reduced use of G-CSF, but less thrombocytopenia. Importantly, there was no 
difference in infectious complications or treatment-related deaths. The incidence of deaths 
during chemotherapy was very low at 1.7%, suggesting adequate management of elderly 
patients in participating centers. In the LNH03-6B trial, a high treatment-related mortality of 
9% was observed in the initial recruitment period, which improved towards the end of the 
study, indicating gain of clinical experience with dose-intensified treatment in elderly patients. 
With 6.5y median follow-up, there was no difference in long-term toxicity, specifically cardiac 
events and secondary malignancies, between arms.  
Dose intensities were high in both arms and as seen in the entire R-CHOP14v21 trial cohort.3 
The low dose intensity of 88% for R-CHOP-14 in the LNH03-6B trial could have potentially 
underestimated efficacy of the 2-weekly regimen. Our results support equivalence of both 
regimens in elderly DLBCL patients when adequate doses are achieved. However, the study 
was not powered for this post-hoc subgroup analysis in elderly patients. 
We did not identify any subgroup of elderly DLBCL patients that showed differential response 
to either regimen, including gender and IPI groups. No difference between treatment arms 
could be seen in patients ≥70y. An analysis of patients ≥80y was not feasible due to low 
numbers (N=20). Moreover, there was no benefit of dose-intense treatment in late 
responders who had not achieved CR/Cru after 4 cycles.  
Consolidation radiotherapy was at the discretion of the investigators and performed in 23% of 
elderly patients with available data. The main indication for radiotherapy was initial bulky or 
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extranodal disease. The benefit of radiotherapy to initial bulk in elderly DLBCL patients is 
reported to be greatest for patients who are not in CR/CRu after induction therapy.8 
Accordingly, most patients in our analysis received radiotherapy to PR or SD at the end of 
treatment, without evidence of a survival benefit for this strategy. However, these data have 
significant limitations (non-randomized approach, small numbers). In addition, no PET-CT 
data were recorded. The on-going DSHNHL OPTIMAL>60 trial will investigate whether 
consolidation radiotherapy can be safely omitted in elderly DLBCL patients who are PET-
negative at the end of treatment.   
Remarkably, PFS of elderly patients was only 8 percentage points worse at 5y compared to 
younger patients (5y-PFS 64% vs. 72%), supporting the concept of treating elderly patients 
with full doses of chemotherapy whenever possible. Toxicities were also similar between 
elderly and younger patients (data not shown), besides a significantly higher rate of grade ≥3 
neutropenia in elderly (P≤0.001).  
Differences between DLBCL of elderly and younger patients have been described on the 
molecular level, with higher frequencies of ABC subtypes, BCL6 rearrangements, gains in 
1q21, 18q21, and 7q21, and a higher genetic complexity associated with increasing age.9 We 
did not observe material differences in the frequency of MYC-R, BCL6- and BCL2-
rearrangements between age groups, nor in the incidence of IHC-based cell-of-origin 
subtypes (data not shown). We found lower frequency of bulky disease and higher B2M 
levels in elderly compared to younger patients, implying differences in disease biology 
between both groups.  
Age-specific clinical and molecular features suggest the need for a separate prognostic 
scoring system for elderly patients. We compared performances of two recently proposed 
prognostic scores for elderly DLBCL (ABE45 and E-IPI4) with the standard IPI and R-IPI in 
our cohort. Both scores use an age cut-off of 70y. ABE4 further incorporates bulky disease 
and separates PS≥1 instead of ≥2. The ABE4 performed best in our cohort, despite bulky 
disease not being significantly associated with patient outcomes. Therefore, separating 
patients with PS 0 from those with PS≥1 could be a more appropriate cut-off in an elderly 
patient group. Both ABE4 and IPI distinguished meaningful prognostic groups for PFS and 
OS. However, clinical utility of the ABE4 score might be limited by the fact that only 9% of 
patients from our cohort were in the high-risk group compared to 14% in the original Czech 
Lymphoma Registry.5 As discussed by Ziepert et al.,10 introduction of new scores have to be 
seen with caution and should only be considered if properly validated and if changing 
patients’ management. The main use of the IPI has been in the context of clinical trials, 
allowing risk-stratification of patients and facilitating comparison of results across trials. A 
NCCN-IPI has recently been proposed which separates three different age groups as risk 
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factors.11 The great disadvantage of this score is that it cannot be used for elderly and young 
patient groups separately and is therefore unsuitable for age-specific DLBCL trials. In 
contrast, the IPI as age-adjusted IPI has been validated in both young and elderly DLBCL.   
In line with previous findings, IHC-based cell-of-origin classification did not impact on 
outcomes, further underscoring limitations of this method. However, final analyses of the 
REMoDL-B trial will reveal if the concept of cell-of-origin classification as prognostic marker 
holds true when assessed prospectively.12 Our combined analysis of FISH data from R-
CHOP14v21 and RICOVER-60 demonstrates for the first time independent prognostic 
significance of both MYC-R and DHL in patients treated with R-CHOP within prospective 
cohorts. A negative prognostic impact of MYC-R and DHL has been reported in several 
heterogeneous DLBCL populations, but did not reach independent significance in trial 
cohorts due to small numbers.3,7 On-going prospective trials will reveal if these patients 
benefit from upfront treatment intensification.  
In conclusion, our data demonstrate excellent short and long-term results with both R-CHOP-
14 and R-CHOP-21 in elderly DLBCL patients. This analysis contributes important 
information to the longstanding discussion about optimal management of the elderly DLBCL 
patient population and provides a detailed analysis of molecular and clinical prognostic 
factors in this age group.  
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Table 1: Baseline characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics R-CHOP-21 
(N=301) 
n (%) 
R-CHOP-14 
(N=303) 
n (%) 
Age (years) 
    60-69 
    ≥70 
 
192 (64%) 
109 (36%) 
 
196 (65%) 
107 (35%) 
Sex 
    Female 
    Male 
 
148 (49%) 
153 (51%) 
 
150 (50%) 
153 (50%) 
WHO performance status 
    0 
    1 
    2 
 
120 (40%) 
132 (44%) 
49 (16%) 
 
143 (47%) 
118 (39%) 
42 (14%) 
Stage (N=596) 
    IA 
    IB 
    II 
    III 
    IV 
 
9 (3%) 
6 (2%) 
90 (30%) 
91 (31%) 
102 (34%) 
 
9 (3%) 
7 (2%) 
83 (28%) 
104 (35%) 
95 (32%) 
Bulk (N=601) 139 (47%) 126 (42%) 
B symptoms 121 (40%) 134 (44%) 
Elevated LDH 200 (66%) 197 (65%) 
>1 extranodal sites 94 (31%) 82 (27%) 
IPI score 
    1 
    2 
    3 
    4 
    5 
 
48 (16%) 
75 (25%) 
98 (33%) 
66 (22%) 
14 (5%) 
 
44 (15%) 
90 (30%) 
104 (34%) 
56 (18%) 
9 (3%) 
Subtype (N=317) 
    GCB 
    non-GCB 
 
76 (50%) 
77 (50%) 
 
82 (50%) 
82 (50%) 
β2-microglobulin ≥3mg/L (N=371) 88 (51%) 102 (52%) 
Albumin ≤35g/L (N=598) 100 (34%) 86 (29%) 
MYC rearrangement (N=217) 9 (9%) 14 (12%) 
BCL2 translocation (N=220) 26 (25%) 33 (28%) 
BCL6 rearrangement (N=218) 17 (16%) 30 (26%) 
Double-hit abnormality (N=215) 5 (5%) 9 (8%) 
Table 2: Most common grade ≥3 toxicities and cause of treatment-related deaths 
 R-CHOP-21 (N=301) R-CHOP-14 (N=303) 
 Any Grade Grade ≥3 Any Grade Grade ≥3 
All toxicities 292 (97%) 216 (72%) 299 (99%) 182 (60%) 
     
Neutropenia 224 (74%) 185 (61%) 138 (46%) 109 (36%) 
Thrombocytopenia 73 (24%) 22 (7%) 112 (37%) 37 (12%) 
Anemia 60 (20%) 6 (2%) 95 (31%) 14 (5%) 
Infection 145 (48%) 71 (24%) 146 (48%) 71 (23%) 
Fever 70 (23%) 16 (5%) 56 (18%) 16 (5%) 
Mucositis 143 (48%) 4 (1%) 167 (55%) 8 (3%) 
Nausea 188 (62%) 7 (2%) 151 (50%) 12 (4%) 
Vomiting 98 (33%) 7 (2%) 82 (27%) 9 (3%) 
Diarrhoea 109 (36%) 12 (4%) 113 (37%) 16 (5%) 
Constipation 185 (61%) 7 (2%) 160 (53%) 8 (3%) 
Neurological 167 (55%) 23 (8%) 183 (60%) 36 (12%) 
Fatigue 240 (80%) 31 (10%) 252 (83%) 40 (13%) 
Bone pain 68 (23%) 7 (2%) 102 (34%) 6 (2%) 
Cardiac 29 (10%) 2 (1%) 29 (10%) 9 (3%) 
Treatment-related deaths: 
3 in R-CHOP-21: 2 non-neutropenic sepsis, 1 neutropenic sepsis 
7 in R-CHOP-14: 2 non-neutropenic sepsis, 1 neutropenic sepsis, 1 renal failure,  3 not 
specified 
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Table 3: Response to treatment 
End of treatment response R-CHOP-21 
(N=274) 
n (%) 
R-CHOP-14 
(N=274) 
n (%) 
Complete response (CR) 145 (53%) 119 (43%) 
Unconfirmed complete response (CRu) 39 (14%) 50 (18%) 
Partial response 64 (23%) 80 (29%) 
Stable disease 16 (6%) 16 (6%) 
Progressive disease or relapse 10 (4%) 9 (3%) 
CR/CRu 184 (67%) 169 (62%) 
Overall response rate 248 (91%) 249 (91%) 
 
 
 
 
  
 
 
Figure 1: Kaplan-Meier curves of PFS and OS in (A) patients over 60 years and (B) patients over 70 years  
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Supplement 
Patients and Methods 
In the phase 3 UK NCRI R-CHOP14v21 trial, patients aged 18 years or older with untreated 
stage IA bulky or stage IB-IV DLBCL were randomly assigned between 2005 and 2008 to 
receive either 8 cycles R-CHOP-21 or 6 cycles R-CHOP-14 (+ G-CSF) with two additional 
rituximab applications. Doses of rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisolone were based on the original GELA and DSHNHL regimens. G-CSF was 
administered on days 4-12 of each cycle. 57% of patients in the R-CHOP-21 arm received 
G-CSF as secondary prophylaxis at the discretion of the investigators. All patients received 
antibiotic prophylaxis with co-trimoxazole until 2 weeks after the end of treatment. 
Performance of consolidation radiotherapy was at the discretion of the investigators. 
Response assessment was performed using contrast-enhanced CT scans after 4 cycles of 
therapy, at the end of treatment, and 3 months and 12 months after completion of treatment. 
Histological diagnosis was confirmed in central histopathology review including 
immunohistochemistry (IHC)-based cell-of-origin classification using the Hans algorithm. The 
R-CHOP14v21 trial was conducted according to the Declaration of Helsinki and all 
participants provided written informed consent. 
604 patients in the R-CHOP14v21 trial were ≥60 years and included in the current subgroup 
analysis (301 in the R-CHOP-21 arm, 303 in the R-CHOP-14 arm). The median follow-up 
was 77.7 months. 
For the joint analysis of MYC-R and DHL in elderly DLBCL patients, molecular data was 
available for 215 R-CHOP14v21 cases and 182 R-CHOP-treated patients from RICOVER-
60. Patients in the combined cohorts with available molecular data were more frequently 
female (52% vs. 46%; P=0.05), had fewer WHO performance status 2 (11% vs. 17%; 
P=0.01), fewer bulky disease (33% vs. 45%; P<0.01) and fewer B symptoms (32% vs. 40%; 
P=0.01) compared to patients without molecular data. Molecular results were not blinded for 
outcome analyses. 
Statistics 
The primary endpoint of the R-CHOP14v21 trial was overall survival (OS). Secondary 
outcome measures were response rate, progression-free survival (PFS) and toxicity.  
Response was assessed by the local treating physician and categorised into complete 
response (CR), unconfirmed CR (CRu), partial response (PR), stable disease (SD) and 
progressive disease (PD) in accordance with the International Workshop Standardized 
2 
 
Response Criteria for Non-Hodgkin Lymphoma. Adverse events were classified using the 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, 
version 3.0). Patients who received at least one cycle of therapy were included in the toxicity 
analyses.  
OS and PFS were calculated by the Kaplan-Meier method with the log-rank comparing 
differences between survival curves. Clinical findings were compared between groups using 
the χ2 or Mann-Whitney U test. A P value of ≤ 0.05 (two-sided) was regarded as significant. 
Multivariate analyses were performed using Cox logistic regression including the following 
variables: age as continuous variable, WHO performance status (PS) 0/1 vs. ≥2, LDH 
normal vs. >upper limit of normal (ULN), Stage I/II vs. III/IV, number of extranodal sites 
involved 0-1 vs. ≥2, gender, bulky disease (diameter ˃10cm) absent vs. present, β2-
microglobulin (B2M) <3mg/L vs. ≥3mg/L, and albumin >35 g/L vs. ≤35 g/L. 
The age-specific prognostic scores elderly IPI (E-IPI) and ABE4 were compared with 
standard IPI and revised IPI (R-IPI). In contrast to the original publication, bulky disease was 
defined as tumour of greater than 10cm (not 7.5cm) to calculate the ABE4 score. 
Performance of scores were compared by global fit criterion AIC (Akaike’s information 
criteria) and discrimination according to CPE (concordance probability estimate), with lower 
values of AIC indicating better fit and higher values of CPE better discrimination 
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Supplementary Tables and Figures 
Table S1: Clinical characteristics according to MYC-R and DHL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics non-MYC  
(N=379) 
n (%) 
MYC-R 
(N=42) 
n (%) 
non-DHL 
(N=374) 
n (%) 
DHL 
(N=23) 
n (%) 
Age (years) 
    60-69 
    ≥70 
 
233 (61%) 
146 (39%) 
 
25 (60%) 
17 (40%) 
 
230 (61%) 
144 (39%) 
 
14 (61%) 
9 (39%) 
Sex 
    Female 
    Male 
 
197 (52%) 
182 (48%) 
 
18 (43%) 
24 (57%) 
 
196 (52%) 
178 (48%) 
 
11 (48%) 
12 (52%) 
Stage III/IV 203 (54%) 19 (45%) 201 (54%) 13 (57%) 
WHO performance status >1 40 (11%) 7 (17%) 39 (10%) 4 (17%) 
Elevated LDH 201 (53%) 26 (62%) 205 (55%) 15 (65%) 
>1 extranodal sites 83 (22%) 9 (21%) 80 (21%) 7 (30%) 
IPI score 
    1 
    2 
    3 
    4 
    5 
 
110 (29%) 
93 (25%) 
110 (29%) 
57 (15%) 
9 (2%) 
 
13 (31%) 
10 (24%) 
10 (24%) 
6 (14%) 
3 (7%) 
 
105 (28%) 
95 (25%) 
110 (29%) 
54 (14%) 
10 (3%) 
 
5 (22%) 
5 (22%) 
7 (30%) 
4 (17%) 
2 (9%) 
Bulk 118 (31%) 19 (45%) 121 (32%) 11 (48%) 
B symptoms 120 (32%) 17 (40%) 118 (32%) 9 (39%) 
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Table S2: Reasons for early termination of treatment 
Reason for early termination R-CHOP-21 
(N=301) 
n  
R-CHOP-14 
(N=303) 
n 
Disease progression (PD) 
        -Death due to PD 
7  
1 
4 
2 
Clinical decision  8 1 
Patient refusal 6  5 
Other medical condition 
        -Death due to other medical condition 
10 
3 
9 
3 
Treatment-related toxicity  
        -Death related to treatment 
27  
3 
19 
7 
Death, other cause or unknown 
Diagnosis changed 
Other 
2 
3 
7 
1 
4 
2 
Not known/missing 1  1 
 
 
Table S3: Survival status and cause of death 
Status and cause of death R-CHOP-21 
(N=301) 
n (%) 
R-CHOP-14 
(N=303) 
n (%) 
Alive without progression 184 (61%) 182 (60%) 
Alive after progression 14 (5%) 18 (6%) 
Dead 103 (34%) 103 (34%) 
    Non-Hodgkin Lymphoma 58 52 
    Treatment related toxicity 3 7 
    Secondary Malignancy 10 11 
    Cardiac Death 6 7 
    Other 26 22 
    Missing 0 4 
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Table S4: Overall survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Univariable Multivariable 
Variable HR (95% CI) P HR (95% CI) P 
R-CHOP-14 arm 0.95 (0.73-1.25) 0.74 1.11 (0.78-1.60) 0.55 
Age (per year) 1.07 (1.05-1.09) <0.0001 1.05 (1.02-1.08) <0.01 
Stage III/IV 1.30 (0.97-1.76) 0.08 1.25 (0.82-1.89) 0.30 
PS >1 1.51 (1.08-2.13) 0.02 1.01 (0.63-1.64) 0.96 
LDH >ULN 1.60 (1.17-2.18) <0.01 1.37 (0.89-2.11) 0.15 
Extranodal sites >1 1.33 (1.00-1.77) 0.05 1.01 (0.68-1.50) 0.96 
B2M ≥3mg/L 2.15 (1.48-3.12) <0.0001 1.54 (1.02-2.33) 0.04 
Bulky disease  1.08 (0.82-1.43) 0.57 0.98 (0.67-1.43) 0.92 
Male sex 1.13 (0.86-1.48) 0.39 1.03 (0.72-1.47) 0.88 
Albumin ≤35g/L 1.79 (1.35-2.36) <0.0001 1.43 (0.97-2.12) 0.07 
6 
 
Table S5: Performance of prognostic scores 
 
Groups  
(no. of factors) 
Patients 
n (%) 
CPE AIC 
IPI (age ≥60y, WHO PS ˃1, Stage III/IV, LDH ˃ULN*, extranodal sites ˃1) 
Low (0-1) 92 (15)   
Low-intermediate (2) 165 (27) 0.571 2486 
High-intermediate (3) 202 (33)   
High (4-5) 145 (24)   
R-IPI (age ≥60y, WHO PS ˃1, Stage III/IV, LDH ˃ULN, extranodal sites ˃1) 
Very good (0) 0 (0)   
Good (1-2) 257 (43) 0.558 2488 
Poor (3-5) 347 (57)   
E-IPI (age ≥70y, WHO PS ˃1, Stage III/IV, LDH ˃ULN, extranodal sites ˃1) 
Low (0-1) 150 (25)   
Low-intermediate (2) 180 (30) 0.546 2494 
High-intermediate (3) 175 (29)   
High (4-5) 99 (16)   
ABE4 (age ≥70y, WHO PS ≥1, bulky disease) 
Low (0) 114 (19)   
Low-intermediate (1) 215 (36) 0.593 2479 
High-intermediate (2) 218 (36)   
High (3) 57 (9)   
*ULN indicates upper limit of normal.  
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Figure S1: Kaplan-Meier curves of PFS and OS according to COO subtypes 
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Figure S2: Kaplan-Meier curves of OS according to different prognostic scores  
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Figure S3: Kaplan-Meier curves of PFS and OS according to consolidation radiotherapy (RT) in 
patients with PR or SD at the end of chemotherapy  
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(N=42) 
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non-DHL 
(N=374) 
n (%) 
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n (%) 
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233 (61%) 
146 (39%) 
 
25 (60%) 
17 (40%) 
 
230 (61%) 
144 (39%) 
 
14 (61%) 
9 (39%) 
Sex 
    Female 
    Male 
 
197 (52%) 
182 (48%) 
 
18 (43%) 
24 (57%) 
 
196 (52%) 
178 (48%) 
 
11 (48%) 
12 (52%) 
Stage III/IV 203 (54%) 19 (45%) 201 (54%) 13 (57%) 
WHO performance status >1 40 (11%) 7 (17%) 39 (10%) 4 (17%) 
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Treatment-related toxicity  
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    Treatment related toxicity 3 7 
    Secondary Malignancy 10 11 
    Cardiac Death 6 7 
    Other 26 22 
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 Univariable Multivariable 
Variable HR (95% CI) P HR (95% CI) P 
R-CHOP-14 arm 0.95 (0.73-1.25) 0.74 1.11 (0.78-1.60) 0.55 
Age (per year) 1.07 (1.05-1.09) <0.0001 1.05 (1.02-1.08) <0.01 
Stage III/IV 1.30 (0.97-1.76) 0.08 1.25 (0.82-1.89) 0.30 
PS >1 1.51 (1.08-2.13) 0.02 1.01 (0.63-1.64) 0.96 
LDH >ULN 1.60 (1.17-2.18) <0.01 1.37 (0.89-2.11) 0.15 
Extranodal sites >1 1.33 (1.00-1.77) 0.05 1.01 (0.68-1.50) 0.96 
B2M ≥3mg/L 2.15 (1.48-3.12) <0.0001 1.54 (1.02-2.33) 0.04 
Bulky disease  1.08 (0.82-1.43) 0.57 0.98 (0.67-1.43) 0.92 
Male sex 1.13 (0.86-1.48) 0.39 1.03 (0.72-1.47) 0.88 
Albumin ≤35g/L 1.79 (1.35-2.36) <0.0001 1.43 (0.97-2.12) 0.07 
Table S5: Performance of prognostic scores 
 
Groups  
(no. of factors) 
Patients 
n (%) 
CPE AIC 
IPI (age ≥60y, WHO PS ˃1, Stage III/IV, LDH ˃ULN*, extranodal sites ˃1) 
Low (0-1) 92 (15)   
Low-intermediate (2) 165 (27) 0.571 2486 
High-intermediate (3) 202 (33)   
High (4-5) 145 (24)   
R-IPI (age ≥60y, WHO PS ˃1, Stage III/IV, LDH ˃ULN, extranodal sites ˃1) 
Very good (0) 0 (0)   
Good (1-2) 257 (43) 0.558 2488 
Poor (3-5) 347 (57)   
E-IPI (age ≥70y, WHO PS ˃1, Stage III/IV, LDH ˃ULN, extranodal sites ˃1) 
Low (0-1) 150 (25)   
Low-intermediate (2) 180 (30) 0.546 2494 
High-intermediate (3) 175 (29)   
High (4-5) 99 (16)   
ABE4 (age ≥70y, WHO PS ≥1, bulky disease) 
Low (0) 114 (19)   
Low-intermediate (1) 215 (36) 0.593 2479 
High-intermediate (2) 218 (36)   
High (3) 57 (9)   
*ULN indicates upper limit of normal.  
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